1. INTRODUCTION {#acm212897-sec-0005}
===============

Along with software advancements to handle increasingly complex calculations, radiation treatment planning is rapidly becoming more and more automated to relieve the planner of tasks that can be readily handled by computers, such as autosegmentation and optimization.[^1^](#acm212897-bib-0001){ref-type="ref"} After localization images of the target are obtained and exported to a treatment planning system (TPS), most of the steps involved in generating the anatomical structure and optimizing the treatment plan can be automated. During the optimization process, the use of automatic planning can reduce human variability while maintaining similar treatment plan quality.

The quality of a manual radiotherapy treatment plan strongly depends on the planner's experience and the planning time[^2^](#acm212897-bib-0002){ref-type="ref"} and, consequently, has large uncertainty. In inverse treatment planning (IMRT/VMAT), the optimization process can be very time consuming because it requires a process of repeated trial‐and‐error. Automatic planning is a solution for standardizing plans, improving the plan quality and decreasing the planning time. There are several commercial tools available for plan automation. The Auto‐Planning (AP) module of Pinnacle (Philips Medical System, Fitchburg, WI) is a software application that simplifies the planning process by using technique scripts and automatic optimization tuning methods. Varian's RapidPlan (Varian Medical Systems, Palo Alto, CA, USA) uses a database of previously used treatment plans to conduct (knowledge‐based planning). Zhang et al.[^3^](#acm212897-bib-0003){ref-type="ref"} implemented a plug‐in (mdaccAutoPlan) in Pinnacle TPS for various tumor sites. Erasmus‐iCycle develops plans based on multicriteria optimization (MCO).[^4^](#acm212897-bib-0004){ref-type="ref"} Some studies imply that planning automation can also be useful for adaptive radiation therapy[^5^](#acm212897-bib-0005){ref-type="ref"} and unbiased comparisons of treatment techniques.[^6^](#acm212897-bib-0006){ref-type="ref"}, [^7^](#acm212897-bib-0007){ref-type="ref"}, [^8^](#acm212897-bib-0008){ref-type="ref"}

The AP module has already been tested in developing plans for head and neck treatments,[^9^](#acm212897-bib-0009){ref-type="ref"}, [^10^](#acm212897-bib-0010){ref-type="ref"}, [^11^](#acm212897-bib-0011){ref-type="ref"}, [^12^](#acm212897-bib-0012){ref-type="ref"} hippocampal avoidance whole‐brain treatment,[^13^](#acm212897-bib-0013){ref-type="ref"} prostate treatments,[^14^](#acm212897-bib-0014){ref-type="ref"} and liver tumor stereotactic body radiotherapy (SBRT).[^15^](#acm212897-bib-0015){ref-type="ref"} The results of these studies show that this approach may improve the efficiency of the optimization process, eliminate the need for repeated trial‐and‐error during the manual planning process, and tend to improve the standardized plan quality. In the AP module, it is still necessary to manually set the beam angles, prescription, and the initial optimization parameters in advance. Generally, the selected initial optimization parameters directly affect the final plan quality. For cases with the same clinical requirements, the AP module uses generic initial parameters in the technique script according to in‐house planning experience. However, these generic initial parameters are not appropriate for some cases, necessitating manual modification via trial‐and‐error. PlanIQ Feasibility (Sun Nuclear Corp, Melbourne, FL) is a tool to estimate the best possible sparing dose of organs at risk (OARs) *a priori* before starting the plan optimization.[^16^](#acm212897-bib-0016){ref-type="ref"} Assuming an ideal fall‐off from the prescription dose at the target boundary, a feasibility dose volume histogram (FDVH) quantitatively determines the regions of a DVH that are impossible (red), difficult (orange), challenging (yellow), and probable (green) for each organ at risk (OAR). The FDVH allows the OAR planning goals to be personalized according to the patient geometry. In the latest version of Pinnacle v16.2, the PlanIQ Feasibility tool has been integrated into the AP module.

In this study, we evaluate an AP workflow in which the plan parameters are personalized using the PlanIQ Feasibility tool, and verify its effectiveness in developing VMAT plans for 10 lung cancer patients. For each case, three plans were developed: a clinically accepted manual plan (MP), an automatic plan generated using generic initial parameters (AP1), and another automatic plan generated using personalized OAR sparing goals according to the FDVH derived using PlanIQ software (AP2). The treatment plans were assessed comprehensively in terms of a new plan quality metric (PQM), which was defined according to the existing PQM[^17^](#acm212897-bib-0017){ref-type="ref"} and quality score, S~D~.[^18^](#acm212897-bib-0018){ref-type="ref"}

2. MATERIALS AND METHODS {#acm212897-sec-0006}
========================

2.A. Patient plan selection and planning objectives {#acm212897-sec-0007}
---------------------------------------------------

Treatment plans of 10 lung cancer patients using conventionally fractionated radiotherapy (CFRT) were selected from recent patient treatment plans. Computer tomography (CT) scans were captured during normal breathing in the supine position with a slice thickness of 5 mm and plane voxel size of 1 mm × 1 mm. The gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV) were contoured by qualified radiation oncologists. Relevant OARs were also delineated, which mainly included the whole lung, spinal cord, and heart. An extra 5 mm margin was added to the spinal cord as the planning organ‐at‐risk volume (PRV). The tumor staging was listed in Table [1](#acm212897-tbl-0001){ref-type="table"}. The prescribed dose was 60 Gy, delivered in 30 fractions.

###### 

Tumor staging.

  Tumor staging   Number of patients
  --------------- --------------------------
  T4              3 (N2 = 2/N3 = 1)
  T3              1 (N0 = 1)
  T2              2 (N2 = 1/N3 = 1)
  T1              4 (N0 = 1/N2 = 2/N3 = 1)
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The planning objectives for the PTV were that the relative volume that receives ≥ 100% of the prescribed dose \> 95%, and the maximum point dose \< 110% of the prescribed dose. The dose coverage and homogeneity of the PTV were assessed based on the dose distribution, the dose volume histogram (DVH), and the trade‐off between the dose delivered to the PTV and OAR sparing. The planning objectives for the OARs were as follows: point dose, spinal cord \< 40 Gy; point dose, spinal cord PRV \< 45 Gy; volume of whole lung receiving more than 5 Gy (V5) not specified though lower doses are preferred, and that receiving more than 20 Gy (V20) \< 28% and that receiving more than 30 Gy (V30) \<20%; mean dose, whole lung (D~mean~) \<17 Gy; and volume of heart receiving more than 30 Gy (V30) \< 40% and that receiving more than 40 Gy (V40) \< 30%. The constraints specified in our department were mainly based on the quantitative analysis of normal tissue effects in the clinic (QUANTEC) guidelines,[^19^](#acm212897-bib-0019){ref-type="ref"}, [^20^](#acm212897-bib-0020){ref-type="ref"}, [^21^](#acm212897-bib-0021){ref-type="ref"} but were more stringent.

2.B. Planning process {#acm212897-sec-0008}
---------------------

During the planning process, the arrangement of beams, dose prescription for the PTV, and initial optimization parameters of each OAR were set by loading a predefined technique script. The workflow of technique script was as follows: (a) two arcs including a clockwise (CW) arc and a counterclockwise (CCW) arc were created, ranging from 181° to 30° for tumors located in the right lung and from 330° to 180° for tumors located in the left lung, and the collimator angle of each beam was set according to the target shape from the beam\'s eye view (BEV). In the technique script, we used Varian Novalis Tx equipped with a 120 multi‐leaf collimator (MLC) (field size: 40 × 40 cm, 5 mm leaf width in central 20 cm of the field, 10 mm leaf width in the outer 20 cm of the field). The settings were as follows: the beam energy was 6 MV, the control point spacing was 4º, and the leaf motion was constrained to 0.5 cm/°. (b) The prescribed dose was defined as 60 Gy, delivered in 30 fractions. (c) The initial settings for the planning objectives were defined according to the clinical requirements. Finally, the AP engine attempted to meet the objectives of target while lowering the dose to the OARs with minimal compromise to the PTV coverage by an optimization process involving six iterative loops and automatic creation of objectives on additional structures. In each progressive loop, target, OARs, and hot/cold spot objectives are added, fine‐tuned with one another, and optimized. The optimizer continues working after the clinical objectives of maximizing target coverage and sparing OARs are met.

Each case includes one manual plan and two automatic plans. The MPs were generated by expert medical physicists with at least 3 yr experience in clinical IMRT/VMAT treatment planning and approved by physicians. The two types of APs were generated by the AP module, one using generic protocol parameters as inputs (AP1) and the other using personalized OAR sparing goals according to the FDVH derived by PlanIQ (AP2). In the Pinnacle v16.2 used in our department, the PlanIQ Feasibility tool was not fully integrated into the TPS at the time of the study. The two software were installed on separated servers with different operating systems (Pinnacle in Unix and PlanIQ in Windows).

A workflow was developed for the AP2, as shown in Fig. [1](#acm212897-fig-0001){ref-type="fig"}. The process involved (a) loading technique script in TPS AP module, (b) exporting the digital imaging and communications in medicine (DICOM) files, radiotherapy (RT) structures, and optimization goals to a shared folder in the Unix system, (c) importing the files to PlanIQ and generating the FDVH; (d) exporting the adjusted optimization goals to the shared folder, and (e) importing the adjusted optimization goals, updating the initial optimization parameters, and starting the AP process.

![Schematic of the workflow for AP2.](ACM2-21-119-g001){#acm212897-fig-0001}

In the Feasibility tool, the adjusted optimization goals for the lungs were between difficult (orange) and challenging (yellow), and those for the heart and spinal cord were between challenging (yellow) and probable (green). In the AP module, the OAR priority parameters were set as follows (lung: high or medium, compromise; heart: low, compromise; spinal cord: high, no compromise).

2.C. Study endpoints {#acm212897-sec-0009}
--------------------

The three plans for each patient were compared in terms of the dosimetric parameters: PQM value, total monitor units, and planning time.

The dosimetric parameters are as follows: (a) The homogeneity index (HI) of the PTV was defined as follows:$$HI = 100\% \times \frac{D2\% - D98\%}{D50\%},$$where D2%, D50%, and D98% are the minimum doses delivered to 2%, 50%, and 98% of the PTV, respectively.[^22^](#acm212897-bib-0022){ref-type="ref"} HI closer to 0 indicates better homogeneity in the PTV. (b) The conformity index (CI) of the PTV is defined as follow:$$CI = \frac{V_{\mathit{PTV}} \times TV}{TV_{\mathit{PTV}}^{2}},$$where V~PTV~ is the volume of the PTV, TV~PTV~ is the portion of the V~PTV~ that is within the prescribed isodose line, and the TV is the treated volume of the prescribed isodose line.[^23^](#acm212897-bib-0023){ref-type="ref"} CI closer to 1 indicate better conformity in the PTV. (c) The dose deposition in the lungs was analyzed in terms of the V5 Gy (%), V20 Gy (%), V30 Gy (%), and mean dose (D~mean~). (d) The dose deposition in the heart was analyzed using V30 Gy (%) and V40 Gy (%). (e) The maximum dose (D~max~) to the spinal cord and spinal cord PRV.

As shown in Table [2](#acm212897-tbl-0002){ref-type="table"}, a PQM scoring procedure with 10 related submetrics was defined for a treatment plan. Each metric is calculated using a unique quantity and PQM value function, and the ranges of the corresponding PQM values were uniformly set from 0 to 10. The quality score, S, of each plan was defined as the sum of PQM values of the subcomponents,[^17^](#acm212897-bib-0017){ref-type="ref"}, [^18^](#acm212897-bib-0018){ref-type="ref"} as follows:$$S = \sum_{i = 1}^{k}S_{i},$$ $$S_{i} = \left\{ \begin{matrix}
{\frac{M_{i} - M_{\mathit{il}}}{M_{\mathit{iu}} - M_{\mathit{il}}} \times S_{i\max},\text{for\ CI}} \\
{\frac{M_{\mathit{iu}} - M_{i}}{M_{\mathit{iu}} - M_{\mathit{il}}} \times S_{i\max}\text{,else}} \\
 \\
\end{matrix} \right.,$$where k is the number of subcomponents, S~i~ is PQM value of the metric corresponding to M~i~, S~imax~ is the maximum PQM value (i.e., the highest score) of M~i~, and M~il~ and M~iu~ are the lower and upper limits of M~i~, respectively. The interval for M~i~ was determined based on recorded data of M~i~ for all ten patients. Thus, the lung cancer plans of all patients in this control experiment could be evaluated using this PQM scoring procedure.

###### 

Evaluation interval of metric parameters along with their value range

  Structure         Metric       PQM value range                      
  ----------------- ------------ ----------------- -------- ---- ---- ----
  PTV               CI           1                 1--2     2    0    10
  HI                0            0--0.2            0.2      0    10   
  Lungs             V5 (%)       27                27--65   65   0    10
  Lungs             V20 (%)      14                14--28   28   0    10
  Lungs             V30 (%)      12                12--20   20   0    10
  Lungs             Dmean (Gy)   9                 9--17    17   0    10
  Heart             V30 (%)      3                 3--40    40   0    10
  Heart             V40 (%)      2                 2--30    30   0    10
  Spinal cord       Dmax (Gy)    31                31--40   40   0    10
  Spinal cord PRV   Dmax (Gy)    35                35--45   45   0    10
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2.D. Statistical analysis {#acm212897-sec-0010}
-------------------------

Wilcoxon signed rank tests were carried out to compare the MP, AP1, and AP2 for all obtained dosimetric data. The statistical analyses were performed in SPSS v17 (IBM Corp), with significance set at *P* \< 0.05.

3. RESULTS {#acm212897-sec-0011}
==========

Figure [2](#acm212897-fig-0002){ref-type="fig"} shows an example of the distribution of the three plans (MP, AP1, and AP2). All three plans satisfied the clinical requirements for all OARs. Table [3](#acm212897-tbl-0003){ref-type="table"} shows the average differences between MP, AP1, and AP2 among all metrics evaluated. There were statistically significant differences for the following parameters: PTV CI, lungs V20 Gy (%), V30 Gy (%), and D~mean~ (Gy); and heart V30 Gy (%), Cord D~max~ (Gy), and Cord PRV D~max~ (Gy). For dose deposition in the lungs, the V20 Gy (%) and V30 Gy (%) of AP2 were lower than those of MP and AP1 (*P* \< 0.05), and the D~mean~ (Gy) of AP2 was lower than that of AP1 (*P* \< 0.05). For dose deposition in the other OARs, the heart V30 Gy (%), cord D~max~ (Gy), and cord PRV D~max~ (Gy) of AP1 and AP2 were lower than those of MP (*P* \< 0.05).

![Dose distributions and DVH curves of the three plans.](ACM2-21-119-g002){#acm212897-fig-0002}

###### 

Averaged differences and 95% confidence interval between each two plans

  Type              MP vs. AP1              MP vs. AP2   AP1 vs. AP2                                                  
  ----------------- ----------------------- ------------ ------------------------ ----------- ----------------------- -----------
  PTV                                                                                                                 
  CI(PTV)           0.00 (−0.10 to 0.10)    0.575        −0.09 (−0.24 to 0.05)    0.241       −0.09 (−0.21 to 0.02)   **0.047**
  HI(PTV)           0.01(−0.01 to 0.02)     0.203        0.00 (−0.02 to 0.02)     0.878       −0.01 (−0.02 to 0.00)   0.059
  Lungs                                                                                                               
  V5 (%)            −1.70 (−5.94 to 2.54)   0.333        −4.49 (−11.86 to 2.87)   0.333       −2.79 (−8.77 to 3.19)   0.285
  V20 (%)           −0.58 (−1.39 to 0.24)   0.169        1.62 (0.19 to 3.04)      **0.037**   2.20 (0.94 to 3.45)     **0.007**
  V30 (%)           −0.76 (−1.93 to 0.40)   0.114        1.06 (−0.17 to 2.29)     **0.037**   1.82 (1.08 to 2.56)     **0.005**
  Dmean (Gy)        −0.26 (−0.61 to 0.08)   0.203        0.30 (−0.08 to 0.68)     0.114       0.56 (0.19 to 0.93)     **0.013**
  Heart                                                                                                               
  V30 (%)           2.02 (0.42 to 3.63)     **0.028**    2.56 (0.20 to 4.92)      **0.028**   0.54 (−0.74 to 1.82)    0.285
  V40 (%)           1.12 (−0.32 to 2.57)    0.139        1.53 (−0.99 to 4.05)     0.203       0.41 (−1.20 to 2.02)    0.799
  Spinal cord                                                                                                         
  Dmax (Gy)         2.25 (1.21 to 3.28)     **0.013**    2.75 (1.12 to 4.39)      **0.017**   0.50 (−0.33 to 1.34)    0.169
  Spinal cord PRV                                                                                                     
  Dmax (Gy)         2.54 (1.26 to 3.82)     **0.007**    2.10 (0.33 to 3.88)      **0.047**   −0.44 (−1.61 to 0.73)   0.285
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Figure [3](#acm212897-fig-0003){ref-type="fig"} shows the relationships of the metrics between AP1 and AP2. The data demonstrate the impact of personalizing the plan parameters compared with traditional AP. Data points for the CI above the dotted line and those for the other parameters below the dotted line indicate that the results of the AP2 were superior.

![Relationships of the metrics between AP1 and AP2 (n = 10).](ACM2-21-119-g003){#acm212897-fig-0003}

The comparisons of plan quality, monitor units, and planning time are shown from Figs [4](#acm212897-fig-0004){ref-type="fig"}, [5](#acm212897-fig-0005){ref-type="fig"}, [6](#acm212897-fig-0006){ref-type="fig"} with the corresponding p‐values obtained from the Wilcoxon signed ranks test. The PQM value of AP2 (52.5 ± 14.3) was higher than that of AP1 (49.2 ± 16.2) and MP (44.8 ± 16.9) (*P* \< 0.05). The monitor units of AP2 (585.9 ± 142.9) and MP (632.8 ± 143.8) were higher than that of AP1 (511.1 ± 136.5) (*P* \< 0.05). The planning times of AP1 (28.2 ± 4.0 min) and AP2 (33.2 ± 4.8 min) were significantly lower than that of MP (72.9 ± 28.5 min) (*P* \< 0.05). Since the planning time of AP2 includes the time needed to adjust the optimization goals in PlanIQ (2.3 ± 0.2 min) and the AP time in the AP module (30.9 ± 4.8 min), the planning time of AP2 was higher than that of AP1 (*P* \< 0.05).

![Box‐whisker plots showing the comparison of PQM values.](ACM2-21-119-g004){#acm212897-fig-0004}

![Box‐whisker plots showing the comparison of monitor units.](ACM2-21-119-g005){#acm212897-fig-0005}

![Box‐whisker plots showing the comparison of planning time.](ACM2-21-119-g006){#acm212897-fig-0006}

4. DISCUSSION {#acm212897-sec-0012}
=============

In this study, we evaluated a technique to personalize plan parameters for VMAT AP in treatment of patients with lung cancer. Three plans (MP, AP1, and AP2) were generated for each case. In AP2, the PlanIQ Feasibility tool was used to generate the personalized plan parameters.

The statistical results in Table [3](#acm212897-tbl-0003){ref-type="table"} show that APs achieved better OAR sparing than the MPs. Furthermore, the dose deposition in the lungs was improved by using personalized parameters; while there was no statistically significant difference between MP and AP1, it appeared that the average lung dose in AP1 was slightly worse than that in MP, even though the priorities of the lung parameters in AP1 were set high. This could be attributed to the use of inappropriate initial settings in AP1 because, although MP and AP1 used the same initial plan parameters, the parameters in MP can be adjusted as needed after the first optimization, while those in AP1 might not be handled well in the following iterations if they are not suitable initially. Therefore, it is beneficial for AP to use personalized initial parameters. Perumal et al.[^24^](#acm212897-bib-0024){ref-type="ref"} conducted an evaluation of plan quality improvements in PlanIQ‐guided AP compared to that in radiation therapy oncology group (RTOG)‐guided AP for five cases of different sites, wherein the dose reduction for the mean dose of total lung was 2.2 Gy for single lung cancer case. According to the statistical results of 10 lung cancer cases in this study, significant reduction in lung mean dose of AP2 (0.56 ± 0.52 Gy) was observed (*P* \< 0.05). The improvement in plan quality can be directly attributed to the higher degree of personalization of plan parameters.

The relationships of the metrics in Fig. [3](#acm212897-fig-0003){ref-type="fig"} showed that AP2 provided superior protection of the lungs. Although there was no statistically significant difference in the CI and HI of the targets, it still can be observed from Fig. [3](#acm212897-fig-0003){ref-type="fig"} that AP2 had inferior results on CI and HI compared to AP1. This could be attributed to the trade‐off of OAR sparing for AP2. Thus, it is necessary to use a quantitative scoring procedure to assess the overall quality of a treatment plan. The plan quality scoring procedure was defined based on concepts of PQM proposed by Benjamin[^17^](#acm212897-bib-0017){ref-type="ref"} and the plan quality score, S~D~, proposed by Bohsung.[^18^](#acm212897-bib-0018){ref-type="ref"} The evaluated metrics were the standard clinical OAR constraints for lung cancer treatment, and the score assignments of different metrics were determined by both physicians and planners. It should be noted that differences in PQM values are only meaningful between different plans for one patient. The features of lung cancer plans approved for clinical treatment showed that the HI and CI of the PTV can be properly sacrificed for OARs sparing, especially for decreasing the dose deposition in the lungs.[^25^](#acm212897-bib-0025){ref-type="ref"} Thus, the score proportion of the OARs was higher than that of the PTV. However, the scoring procedure may differ between different tumor sites. For example, the radiotherapy plans for nasopharynx cancer (NPC) require better dose coverage and homogeneity of PTV than lung cancer plans, the score proportion of PTV should be increased. According to the plan quality scoring procedure, AP2 provided higher quality than either MP or AP1.

The MP generally has more monitor units than AP1 and AP2, and an average increase of 75 MU of AP2 was observed compared to AP1 in this study. For the ten cases in AP2, the initial optimization parameters of the OARs were generally set with more stringent objectives, and the resulting higher modulation could increase monitor units. Several studies indicated that higher modulation could result in greater segment irregularity and lower pass rate in the dose verification.[^26^](#acm212897-bib-0026){ref-type="ref"}, [^27^](#acm212897-bib-0027){ref-type="ref"}, [^28^](#acm212897-bib-0028){ref-type="ref"} In addition, the AP module significantly reduced the planning time, which is consistent with results reported by Hansen et al.[^12^](#acm212897-bib-0012){ref-type="ref"} for head and neck treatments and Gallio et al.[^15^](#acm212897-bib-0015){ref-type="ref"} for liver SBRT (both reporting reductions of more than twice). The planning time of AP1 includes loading the technique script and performing AP. The planning time of AP2 includes loading the technique script, obtaining the personalized optimization parameters from PlanIQ, and performing AP. Because the software platforms are separated and additional time is needed for feasibility analysis, AP2 required more planning time than AP1. Since PlanIQ was not fully integrated into the AP module in the Pinnacle v16.2 used in our department, data transmission between the two separated software was required. According to the ten AP2 plans, the average time required for data transmission was approximately 2 min. If the PlanIQ Feasibility tool is fully integrated into Pinnacle and full‐automatic is achieved, the average planning time by AP2 will be further decreased to approximately 31 min. This time‐saving aspect is particularly important for centers with limited resources as it enables planners to focus on more challenging and complex plans.

Generally, the PlanIQ software was used to output plan quality scores according to the relevant metrics and corresponding scoring functions for each target and OAR. With Feasibility tool, *a priori* estimation of the most feasible DVH for OARs can be generated to initialize the optimization goals. Unlike knowledge‐based planning, the Feasibility tool does not depend on prior experience or a learning database of similar treatment plans. The advantages of the method are its simplicity and minimal commissioning effort involved. However, this simplicity leads to limitations. The dose coverage and homogeneity of targets are ideal and unachievable. It approximates the lowest possible boundary of each OAR DVH without consideration of the other OARs. Similar to Pareto optimal, the actual OAR DVH curves can be driven as close as possible to (but never below) the corresponding FDVH, and no individual OAR objective function can be further improved without sacrificing at least one other. The quantitative regions of DVH for each OAR includes impossible (red), difficult (orange), challenging (yellow), and probable (green). Thus, it is not appropriate to put all estimated objectives in difficult regions. Therefore, *a priori* estimated objectives should be chosen from difficult to probable regions based on the priorities of the OARs.

In AP2, the personalized parameters and priorities for the target and OARs were selected by trial‐and‐error. However, this might be a limitation because different initial settings lead to variable plan quality. Although we made an effort to find an appropriate initial setting, this selection may still result in suboptimal plan quality. To address this problem, we can generate several sets of initial parameters within a reasonable scope, and assign different priorities to target coverage and OAR sparing. Then, we can find a "sweet spot" according to these different initial settings. In this way, it is possible and beneficial to further improve the plan quality.

The results of this study indicate that CFRT plans using the AP2 approach are of superior quality to those using AP1 approach or generated manually. In future study, we will continue to test the performance of the AP2 method in SBRT plans. We expect that, by selecting appropriate personalized initial parameters, the AP2 method can achieve better plan quality than the conventional AP1 method. As the automation of planning process continues to improve, it is anticipated that the automatically generated plans will achieve higher quality in a more efficient way; hence, more exploration in this direction is needed.

5. CONCLUSIONS {#acm212897-sec-0013}
==============

Here, we demonstrated that the use of personalized plan parameters suggested by the PlanIQ Feasibility tool in the AP module of the Pinnacle system provides better quality plans than AP using generic plan parameters. The quality of the plans generated by AP relies on the initial optimization goals, which are generally set by the technique script. By using personalized objectives generated by the PlanIQ Feasibility tool, it is possible to further improve the plan quality and allow planners to use AP in a more effective way. In addition, the planning time of AP was significantly lower than that of MP, and additional time was needed to perform the feasibility analysis for the AP using personalized plan parameters.
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